Successful Pre-IND FDA Meeting and Continued Progress Toward First-in-Human Trial of ERNA-101 in Ovarian Cancer Announced
“We are very pleased with the outcome of our engagement with the FDA,” said Sanjeev Luther, President and CEO of Ernexa Therapeutics. “The Agency’s feedback validates our development strategy and gives us the green light to move forward with urgency. With tech transfer now in progress, we are operating at full speed to bring our first-in-human studies online in 2026. This is a major step toward delivering transformative cell therapies to patients with serious and underserved diseases.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the